AbbVie vs Zoetis
AbbVie (ABBV) and Zoetis (ZTS) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $506B
- Last close
- $286.20
- 12 months
- +24.7%
- Market value
- $31.1B
- Last close
- $79.11
- 12 months
- −31.7%
At a glance
- The biggest part of Zoetis's revenue is Vaccines, 21% of the total in its last annual report.
- By market value, AbbVie ($505.9B) is about 16 times Zoetis ($31.1B).
- Over the last 12 months AbbVie's share price moved +24.7% and Zoetis's −31.7%; against the S&P 500 that is +19.0 points and −37.5 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Zoetis 28.2%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 0 at Zoetis; members of Congress disclosed 1 trade in AbbVie and 4 in Zoetis.
- Next results: AbbVie Feb 2, 2027, Zoetis Feb 10, 2027.
How each one makes money: AbbVie revenue · Zoetis revenue
Share prices on one chart
AbbVie and Zoetis, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Zoetis ZTSNYSE · Pharmaceuticals | |
|---|---|---|
| Size and profitability | ||
| Market value | $506B | $31.1B |
| Revenue, last fiscal year | $61.2B | $9.47B |
| Net income, last fiscal year | $4.23B | $2.67B |
| Net marginNet income as a share of revenue | 6.9% | 28.2% |
| Free cash flow | $17.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
AbbVie against
Common questions
How is AbbVie different from Zoetis?
AbbVie (ABBV) is in Pharmaceuticals on NYSE, with $61.2B of revenue in its last fiscal year and a net margin of 6.9%. Zoetis (ZTS) is in Pharmaceuticals on NYSE, with $9.47B of revenue in its last fiscal year and a net margin of 28.2%. The biggest part of Zoetis's revenue is Vaccines, 21% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do AbbVie and Zoetis compare in size?
AbbVie has the larger market value: AbbVie $506B and Zoetis $31.1B, at the last close.
Whose share price rose more over the last 12 months, ABBV or ZTS?
Over the last 12 months AbbVie moved +24.7% and Zoetis −31.7%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Zoetis?
Both have the same number of open-market insider purchases since 2006 (25).
Do members of Congress trade ABBV or ZTS?
In the last 12 months, members of Congress disclosed 9 trades in AbbVie (ABBV) and 14 in Zoetis (ZTS).
When did insiders last buy ABBV and ZTS?
AbbVie: Mar 30, 2020. Zoetis: May 13, 2026.
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageZoetis pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-zts













